In the Claims:

Claim 1 (currently amended) A pharmaceutical combination composition consisting essentially of, as <u>individual</u> active ingredients, <u>a</u>) a NO synthase <u>inhibitory</u> substance <u>inhibitor being a compound of amino acid type selected from the group consisting of L-arginine derivatives and a compound of the amidine family and b) a metabolic antioxidant substance possessing at least two thiol groups and which intervene(s) in the redox status of thiol groups, and optionally a pharmaceutically acceptable support, said composition having the dual activity of inhibiting the NO synthase and antioxidant, a) and b) being in separated form.</u>

Claims 2-3 (cancelled).

Claim 4 (previously presented) A pharmaceutical composition of Claim 1 wherein the metabolic antioxidant is selected from the group consisting of dithiothreitol, pyritinol, lipoic acid and its derivatives, the dimeric disulfide derivatives of penicillamine or N-acetylcysteine, and peptides comprising at least two cysteine residues.

Claims 5 to 9 (cancelled).

Claim 10 (currently amended) A pharmaceutical composition of Claim 1 wherein the NO synthase inhibitor is selected from the group consisting of L-nitro-arginine, L-nitro-arginine methyl ester, L-N-monomethylarginine, aminoguanidine,

agmatine, 2-amino-1-(methylamino)benzimidazole, 5-nitro-indazole, 6-nitro-indazole, 7-nitro-indazole, 1,2-(trifluoromethylphenyl)phenyl)imidazole, 2-amino-4-methyl-6-(2-aminoethyl)pyridine, 2-iminopiperidine, 2-iminohomopiperidine, 2-imino-5,6-dihydro-1,3-thiazine, 2-imino-5,6-dihydro-1,3-oxazine, 2-iminotetrahydropyrimidine, and N-phenyl-2-thiophene-carboximidamine, S-ethylisothiourea, S-methyl-L-thiocitrulline and S-ethyl-L-thiocitrulline.

Cancel Claims 11 and 12.

Claims 13-36 (cancelled).